This article discussed the study published by Lancet two days ago that showed that previous SARS-CoV-2 infection protects against re-infection.
It is a large study considering it included 65 studies from 19 countries. The result showed that previous infection is highly protective against the Wuhan type, which they called ancestral, and the alpha, beta, and delta variants.
Definitions
Re-infection in this study means testing positive again for SARS-CoV-2 after 90 days. It includes those who are asymptomatic or have mild and moderate symptoms.
Symptomatic infection was defined as re-infection with SARS-CoV-2 with symptoms, which may include new or increased cough, new or increased shortness of breath, chills, new or increased muscle pain, loss of taste or smell, sore throat, diarrhea, and vomiting.
Severe infections mean hospitalization or death.
Duration and levels of protection
Protection against Re-infection
Protection from re-infection from ancestral, alpha, and delta variants declined over time but remained at 78.6% (49.8–93.6) at 40 weeks (10 months).
Protection against re-infection by the Omicron BA.1 variant declined more rapidly and was estimated at 36.1% (24.4–51.3) at 40 weeks.
Protection against Severe disease
The best indicator of the efficacy of natural immunity is how it protects against a severe disease that leads to hospitalization and prevents deaths.
Protection against severe disease remained high for all variants, with 90.2% (69.7–97.5) for ancestral, alpha, and delta variants and 88.9% (84.7–90.9) for Omicron BA.1 at 40 weeks.
The protection level for Omicron was lower. The Omicron BA.1 variant was 45.3%, and for symptomatic Omicron BA.1 disease, it is 44%.
For all the variants, including BA.1, natural immunity has an effectiveness of more than 78% against severe disease (hospitalization and death)
The figure below shows the pooled estimate of protection from past SARS-CoV-2 infection against re-infection, symptomatic disease, and severe disease by variant, and the number of included studies in each meta-analysis estimate.
Authors’ Conclusion
The authors recommend that natural immunity be considered when making vaccination policies or mandates.
Protection from severe disease was high for all variants.
The immunity conferred by past infection should be weighed alongside protection from vaccination when assessing future disease burden from COVID-19, providing guidance on when individuals should be vaccinated, and designing policies that mandate vaccination for workers or restrict access, on the basis of immune status, to settings where the risk of transmission is high, such as travel and high-occupancy indoor settings.
Comment:
Natural immunity is better than vaccine immunity
How does natural immunity compare to “vaccine” protection? The World Health Organization and the US FDA require COVID “vaccines” to have a high efficacy rate of 50% or above to be approved.
Bivalent shots have substandard efficacy. I used CDC data to show that.
CDC data: Sub-par efficacy of the Bivalent COVID shots
The role of big pharma in reinfections
The study included all research papers until September 2022. The Pfizer mRNA shot was started on December 2019. Paxlovid and Molnupiravir were released in December 2021.
How many of these re-infections were caused by those products?
A study published in Science Immunology showed that the Pfizer jab switches the antibodies to the non-inflammatory IgG4 and allows infections.
- Pfizer mRNA shots Switch Antibodies to Non-Neutralizing IgG4
- Three Studies Link High IgG4 to Severe COVID-19
How many Omicron variants arose due to molnupiravir? A new preprint study showed that molnupiravir led to the rapid formation of hundreds of SARS-CoV-2 mutations.
I discussed that paper in – Molnupiravir Causes Hundred of SARS-CoV-2 Mutations
And how many re-infections are due to Paxlovid? Read about them at:
Natural immunity is a wonderful God-given mechanism. Despite the blunders of big pharma, we are still around. I contend that if effective medications like ivermectin, hydroxychloroquine, and vitamin D were allowed to be prescribed freely as out-patient, the number of severe diseases would have been lower.
Hopefully, this study will convince policymakers to change their vaccine mandates.
Truth heals. Lies kill. Don’t Get Sick!
Knowledge about Covid-19 is rapidly evolving. Stay current by subscribing. Feel free to share and like.
Follow me on Gettr, Truth Social, Gab, Parler, Twitter, Facebook, Follow, and Telegram.
If you find value in this website, please consider buying a coffee to show your support.
Natural immunity articles:
- Natural immunity beats the Pfizer and Moderna shots
- Natural immunity vs. Pfizer BNT162b2 vs. Coronavac
- Naturally acquired antibodies from COVID-19 last up to 20 months
- Ultrapotent antibodies from natural infection against diverse and highly transmissible SARS-CoV-2 variants
- COVID-19 recovered immunity vs. Pfizer BNT162b2 vs. Coronavac
- The COVID-19 reinfection risk at 18 months is low at 0.32%
- Naturally acquired antibodies from COVID-19 last up to 20 months
- T cells from previous infections and shots are protective against the Omicron variant
- Omicron infections elicit neutralizing antibodies against variants of concern
- High Anti-SARS-CoV-2 Antibodies Among the Unvaccinated in Bangui, Central African Republic
- COVID Vaccines are Non-Sterilizing and Can Lead to More Infectious Variants
- Study Shows Decreased Antibody Response to Breakthrough Infections
- Pre-Existing T-Cells Stop COVID-19 Before it Starts
- Harvard: Immunity from mild COVID-19 infection much better than vaccination
Reference:
COVID-19 Forecasting Team. Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis. The Lancet. DOI:https://doi.org/10.1016/S0140-6736(22)02465-5
© 2018 – 2023 Asclepiades Medicine, LLC. All Rights Reserved
DrJesseSantiano.com does not provide medical advice, diagnosis, or treatment
As an Amazon Associate, I earn from qualifying purchases.